Klaus Schmierer

37PUBLICATIONS
76CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)People with disabilityGene and molecular therapyEpigenetics (incl. genome methylation and epigenomics)Neurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Jul 06, 2026
Transfusion-Associated Graft-Versus-Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

|May 01, 2026
Understanding the Unmet Needs of People with MS at Diagnosis and Throughout Their Care Journey: Insights from a Survey-Based Study.

|Aug 04, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Klaus Schmierer, Heinz Wiendl, Frederik Barkhof

|Jun 27, 2025
Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility.

David Baker, Lars Alfredsson, Anna Karin Hedström

|Jan 23, 2025
Neurofilament heavy chain in secondary progressive multiple sclerosis.

Floriana De Angelis, Francesca Ammoscato, Richard A Parker

|Dec 11, 2024
Effects of cladribine on intrathecal and peripheral B and plasma cells.

Kimberley Allen-Philbey, Sophie Stephenson, Gina Doody

Pageof 7

Frequent Collaborators

7 joint publications

David Baker

5 joint publications

Kimberley Allen-Philbey

4 joint publications

Emma C Tallantyre

3 joint publications

Gavin Giovannoni